Fifth Third Bancorp
CLDX icon

Fifth Third Bancorp’s Celldex Therapeutics CLDX Stock Holding History

Fifth Third Bancorp’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14K Hold
31
– – ﹤0.01% 4161
2026
Q1 		$969 Buy
+31
New +$845 ﹤0.01% 4134
2017
Q3 		– Sell
-2
Closed – – 2197
2017
Q2 		$0 Hold
2
– – ﹤0.01% 2189
2017
Q1 		$0 Buy
+2
New +$104 ﹤0.01% 2121
2014
Q4 		– Sell
-9
Closed -$2K – 2378
2014
Q3 		$2K Hold
9
– – ﹤0.01% 2268
2014
Q2 		$2K Hold
9
– – ﹤0.01% 2252
2014
Q1 		$2K Buy
9
+3
+50% +$1.15K ﹤0.01% 2226
2013
Q4 		$2K Buy
+6
New +$2.31K ﹤0.01% 2066

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fifth Third Bancorp's CLDX Position: Q2 2026 in Review

Fifth Third Bancorp held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 31 shares worth $1.14K. The position accounts for ﹤0.01% of the portfolio, ranked #4161.

Fifth Third Bancorp first reported a position in CLDX in Q4 2013 and has held it in 8 quarters since. The position peaked at $2K in Q3 2014. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Fifth Third Bancorp held 31 shares of Celldex Therapeutics worth $1.14K as of Q2 2026.
  • Fifth Third Bancorp left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #4161 holding.
  • Fifth Third Bancorp first reported a position in Celldex Therapeutics in Q4 2013 and has held it in 8 quarters since.
  • Fifth Third Bancorp's Celldex Therapeutics position peaked at $2K in Q3 2014.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.